Piramal Pharma Limited has announced its financial results for the period ending December 31, 2025, encompassing both the third quarter (Q3) and the first nine months (9M) of fiscal year 2026. The company’s announcement, released via a press release dated January 28, 2026, also detailed changes within its senior management personnel (SMP) and key managerial personnel (KMP). These developments were communicated to the Exchange.
The press release from Piramal Pharma serves to inform stakeholders about the company’s financial performance during the specified period and to provide updates on its leadership structure. Specific details regarding the financial results and the nature of the management changes were included in the announcement. The changes included adjustments in the roles of the Company Secretary and Compliance Officer.
Investors and analysts will likely scrutinize the Q3 and 9M FY26 results to assess Piramal Pharma’s performance and strategic direction. The changes in SMP and KMP will also be of interest, as they could signal shifts in the company’s strategic priorities or operational focus. The announcement was made in accordance with regulatory requirements, ensuring transparency for all stakeholders.
Further details on the financial performance, as well as the names and roles of the personnel affected by the management changes, can be found in the official press release accessible through the provided source.
Key Takeaways:
- Piramal Pharma Limited released Q3 and 9M FY26 financial results.
- The announcement included changes in senior management personnel, including the Company Secretary and Compliance Officer.
- The press release was issued on January 28, 2026.
Source: NSE News – Latest Announcements
About the Author
